About the Technology
Treatment using the SyqeAir Inhaler delivers a metered dose of THC (in micrograms) along with the other cannabinoids and terpenes found in a full-spectrum cannabis inflorescence. The dose is personalized to the patient by a nurse and selected (out of 4 doses) at the push of a button. And although human inhalation is not metered or consistent, the innovative technologies we developed and embedded within the SyqeAir Inhaler allow for the delivery of the entire selected amount into the lungs, ensuring consistent treatment. How does it work?
The SyqeAir Inhaler Combines a Number of Groundbreaking Technologies:
Electronic Selective-Dose™
A mechanism for administrating a personalized and metered dose, in increments of 250 micrograms: 250, 500, 750, and 1,000 mcg (with reference to Δ9-THC).
ActiveFlow™
Every person is characterized by a different inhalation duration and intensity. The ActiveFlow™ mechanism is designed to create an optimal absorption of the selected dose during the inhalation.
PulseBreath™
Patients who have tried using medical inhalers know that adapting to the manufacturer’s instructions is difficult. In practice, partial compliance with the manufacturer’s instructions does not guarantee that the full dose prescribed to the patient will reach its destination.
The SyqeAir Inhaler – the only medical device that incorporates the PulseBreath™ and ActiveFlow™ mechanisms, ensures that the entire amount of THC, along with the other active ingredients in the cannabis inflorescence, reaches the lungs and thus improves its absorption in the body1-2.
SyqeAir Inhaler
Reduction in pain intensity with minimum psychoactive adverse effects for optimal quality of life.
For more information, contact us:
- Almog, S., et al. (2020). The pharmacokinetics, efficacy, and safety of a novel selective‐dose cannabis inhaler in patients with chronic pain: a randomized, double‐blinded, placebo‐controlled trial. European Journal of Pain, 24(8), 1505-1516.
- Eisenberg, E., et al. (2014). The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. Journal of Pain & palliative care pharmacotherapy, 28(3), 216-225.
